This fall, many preemies will face a deadly seasonal virus known as RSV with no protection.

It’s a common virus with flu-like symptoms. But Respiratory Syncytial Virus can endanger premature infants because of their underdeveloped lungs and fragile immune systems.

Some preemies don't survive it. 

The financial and emotional cost of RSV can be devastating. 

• Hospital stays in the NICU or PICU
• Hospital bills
• Child care for other siblings 
• Missed work
• Lost wages

 No vaccine for RSV exists, but a preventive medication can help. Known as palivizumab, it is FDA approved for ALL premature infants. However, a policy from the American Academy of Pediatrics recommends that only severely premature infants (born before 29 weeks) receive it. That policy allows health plans to restrict access to preventive treatment for a majority of preemies, causing these fragile infants to unnecessarily suffer.  

Until the American Academy of Pediatrics revises its policy to follow the treatment's FDA label and allow all premature infants access, these babies and their families will continue to suffer.